World Journal of Surgery · 2008 · 158 citations · 39 references
MedicineClinical SciencesSurgeryGastroenterologyGastrointestinal PharmacotherapyGeneral SurgeryEsophageal DiseasesEsophageal SurgeryGastroesophageal Reflux DiseaseGastroesophageal Reflux Disease CareGastrointestinal InterventionsGastrointestinal SurgeryAbdominal HerniasAnti-reflux SurgeryHiatal Hernia RepairPharmacologic Therapy For GerdPostoperative Esophageal ComplicationsPostoperative Gastrointestinal BleedingProton Pump InhibitionSurgical Management Of Gerd
BACKGROUND: A novel transoral incisionless fundoplication (TIF) procedure using the EsophyX system with SerosaFuse fasteners was designed to reconstruct a full-thickness valve at the gastroesophageal junction through tailored delivery of multiple fasteners during a single-device insertion. The safety and efficacy of TIF for treating gastroesophageal reflux disease (GERD) were evaluated in a prospective multicenter trial. METHODS: Patients (n = 86) with chronic GERD treated with proton pump inhibitors (PPIs) were enrolled. Exclusion criteria included an irreducible hiatal hernia > 2 cm. RESULTS: The TIF procedure (n = 84) reduced all hiatal hernias (n = 49) and constructed valves measuring 4 cm (2-6 cm) and 230 degrees (160 degrees -300 degrees ). Serious adverse events consisted of two esophageal perforations upon device insertion and one case of postoperative intraluminal bleeding. Other adverse events were mild and transient. At 12 months, aggregate (n = 79) and stratified Hill grade I tight (n = 21) results showed 73% and 86% of patients with >or=50% improvement in GERD health-related quality of life (HRQL) scores, 85% discontinuation of daily PPI use, and 81% complete cessation of PPIs; 37% and 48% normalization of esophageal acid exposure; 60% and 89% hiatal hernia reduction; and 62% and 80% esophagitis reduction, respectively. More than 50% of patients with Hill grade I tight valves had a normalized cardia circumference. Resting pressure of the lower esophageal sphincter (LES) was improved significantly (p < 0.001), by 53%. EsophyX-TIF cured GERD in 56% of patients based on their symptom reduction and PPI discontinuation. CONCLUSION: The 12-month results showed that EsophyX-TIF was safe and effective in improving quality of life and for reducing symptoms, PPI use, hiatal hernia, and esophagitis, as well as increasing the LES resting pressure and normalizing esophageal pH and cardia circumference in chronic GERD patients.
39
The gastroesophageal flap valve: in vitro and in vivo observations
Lucius D. Hill, Richard A. Kozarek, S. J. M. Kraemer et al. · Gastrointestinal Endoscopy · 1996 · 459 citations
Quality of life scale for gastroesophageal reflux disease.
Vic Velanovich, S Vallance, John R. Gusz et al. · PubMed · 1996 · 389 citations